Article

Age-at-onset linkage analysis in Caribbean Hispanics with familial late-onset Alzheimer's disease

The Taub Institute on Alzheimer's Disease and the Aging Brain, Columbia University, New York, NY 10032, USA.
Neurogenetics (Impact Factor: 2.66). 03/2008; 9(1):51-60. DOI: 10.1007/s10048-007-0103-3
Source: PubMed

ABSTRACT The aim of the study was to identify chromosomal regions that may harbor putative genetic variants influencing age at onset in familial late-onset Alzheimer's disease (LOAD). Data from a genome-wide scan that included genotyping of APOE were analyzed in 1,161 individuals from 209 families of Caribbean Hispanic ancestry with a mean age at onset of 73.3 years multiply affected by LOAD. Two-point and multipoint analyses were conducted using variance component methods using 376 microsatellite markers with an average intermarker distance of 9.3 cM. Family-based test of association was also conducted for the same set of markers. Age at onset of symptoms among affected individuals was used as the quantitative trait. Our results showed that the presence of APOE-epsilon4 lowered the age at onset by 3 years. Several candidate loci were identified. Using linkage analysis strategy, the highest logarithm of odds (LOD) scores were obtained using a conservative definition of LOAD at 5q15 (LOD = 3.1), 17q25.1 (LOD = 2.94), 14q32.12 (LOD = 2.36), and 7q36.3 (LOD = 2.29) in a model that adjusted for APOE-epsilon4 and other covariates. Both linkage and family-based association identified 17p13 as a candidate region. Family-based association analysis showed markers at 12q13 (p = 0.00002), 13q33 (p = 0.00043), and 14q23 (p = 0.00046) to be significantly associated with age at onset. The current study supports the hypothesis that there are additional genetic loci that could influence age at onset of late onset Alzheimer's disease. The novel loci at 5q15, 17q25.1, 13q33, and 17p13 and the previously reported loci at 7q36.3, 12q13, 14q23, and 14q32 need further investigation.

Download full-text

Full-text

Available from: Joseph H Lee, Sep 03, 2015
0 Followers
 · 
154 Views
 · 
77 Downloads
  • Source
    • "Another study reported the existence of a susceptibility locus in 14q32.12 near marker D14S617 in a Caribbean Hispanic cohort of 1161 individuals from 209 families (Lee et al., 2008). The UNC-79 gene lies in a region at less than 3Mb from this marker. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Ion channels are crucial components of cellular excitability and are involved in many neurological diseases. This review focuses on the sodium leak, G protein-coupled receptors (GPCRs)-activated NALCN channel that is predominantly expressed in neurons where it regulates the resting membrane potential and neuronal excitability. NALCN is part of a complex that includes not only GPCRs, but also UNC-79, UNC-80, NLF-1 and src family of Tyrosine kinases (SFKs). There is growing evidence that the NALCN channelosome critically regulates its ion conduction. Both in mammals and invertebrates, animal models revealed an involvement in many processes such as locomotor behaviors, sensitivity to volatile anesthetics, and respiratory rhythms. There is also evidence that alteration in this NALCN channelosome can cause a wide variety of diseases. Indeed, mutations in the NALCN gene were identified in Infantile Neuroaxonal Dystrophy (INAD) patients, as well as in patients with an Autosomal Recessive Syndrome with severe hypotonia, speech impairment, and cognitive delay. Deletions in NALCN gene were also reported in diseases such as 13q syndrome. In addition, genes encoding NALCN, NLF- 1, UNC-79, and UNC-80 proteins may be susceptibility loci for several diseases including bipolar disorder, schizophrenia, Alzheimer's disease, autism, epilepsy, alcoholism, cardiac diseases and cancer. Although the physiological role of the NALCN channelosome is poorly understood, its involvement in human diseases should foster interest for drug development in the near future. Toward this goal, we review here the current knowledge on the NALCN channelosome in physiology and diseases.
    Frontiers in Cellular Neuroscience 05/2014; 8:132. DOI:10.3389/fncel.2014.00132 · 4.18 Impact Factor
  • Source
    • "The link between SORL1 and AD was also supported by the identification of AD-associated allelic variants in distinct regions of the SORL1 gene in different populations. These results also suggested that these variants might map in still-unknown intronic regulatory regions that might govern cell-type-or tissue-specific expression of SORL1 (Bruni et al., 2007; Hinerfeld et al., 2007; Klein et al., 2007; Lee et al., 2007; Matsui et al., 2007; Rogaeva et al., 2007; Shibata et al., 2007; Lee et al., 2008; Xiao et al., 2008; Massone et al., 2012). Thus, expression of these variants might affect AD risk by altering the physiological role of SORL1 in the processing of APP holoprotein (Schmidt et al., 2012). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Recent studies indicated sortilin-related receptor 1 (SORL1) to be a risk-gene for late-onset Alzheimer's Disease (AD), although its role in the aetiology and/or progression of this disorder is not fully understood. Here, we report the finding of a novel non-coding (nc) RNA (hereafter referred to as 51A) that maps in antisense (AS) configuration in intron 1 of SORL1 gene. 51A expression drives a splicing shift of SORL1 from the synthesis of the canonical long protein variant 1 to an alternatively spliced protein form. This process, resulting in a decreased synthesis of SORL1 variant 1, is associated with an impaired processing of APP, leading to increase of Aβ formation. Interestingly, we found that 51A is expressed in human brains, being frequently up-regulated in cerebral cortices from Alzheimer's disease patients. Altogether these findings document a novel ncRNA-dependent regulatory pathway that might have relevant implications in neurodegeneration.
    Disease Models and Mechanisms 03/2013; 6(2):424-433. DOI:10.1242/dmm.009761 · 5.54 Impact Factor
  • Source
    • "Some studies of Hispanics (from various countries of origin) in the U.S. have described a significantly younger age of onset of Alzheimer's disease (AD) dementia, greater cognitive impairment at the time of presentation, and relatively lower frequency of apolipoprotein E ␧4 compared to other ethnoracial groups [1] [2]. Explanations for these features include genetic mutations and polymorphisms associated with early onset and familial AD [3] [4], recruitment and/or self-selection bias among the patients who agreed to research assessment, language and cultural bias in assessment measures, lower education and socioeconomic status conferring reduced resilience to the clinical expression of AD, and greater psychiatric morbidity [2]. As we began to address these factors, we discovered a high frequency of the previously described [5] [6] Gly206Ala (glycine to alanine amino acid substitution at codon 206 in exon 7) mutation in the presenilin 1 gene (PSEN1) among Puerto Rican Hispanics with neurodegenerative dementias assessed at our Alzheimer's Disease Center (ADC). "
    [Show abstract] [Hide abstract]
    ABSTRACT: The frequency and clinical and pathological characteristics associated with the Gly206Ala presenilin 1 (PSEN1) mutation in Puerto Rican and non-Puerto Rican Hispanics were evaluated at the University of Pennsylvania's Alzheimer's Disease Center. DNAs from all cohort subjects were genotyped for the Gly206Ala PSEN1 mutation. Carriers and non-carriers with neurodegenerative disease dementias were compared for demographic, clinical, psychometric, and biomarker variables. Nineteen (12.6%) of 151 unrelated subjects with dementia were discovered to carry the PSEN1 Gly206Ala mutation. Microsatellite marker genotyping determined a common ancestral haplotype for all carriers. Carriers were all of Puerto Rican heritage with significantly younger age of onset, but otherwise were clinically and neuropsychologically comparable to those of non-carriers with AD. Three subjects had extensive topographic and biochemical biomarker assessments that were also typical of non-carriers with AD. Neuropathological examination in one subject revealed severe, widespread plaque and tangle pathology without other meaningful disease lesions. The PSEN1 Gly206Ala mutation is notably frequent in unrelated Puerto Rican immigrants with dementia in Philadelphia. Considered together with the increased prevalence and mortality of AD reported in Puerto Rico, these high rates may reflect hereditary risk concentrated in the island which warrants further study.
    Journal of Alzheimer's disease: JAD 10/2012; 33(4). DOI:10.3233/JAD-2012-121570 · 4.15 Impact Factor
Show more